# Minkang Biological Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/minkang-biological-group

- Industry: Medical Devices & Equipment
- Headquarters: Tianjin, China
- Website: www.minkangshengwu.com
- Total disclosed funding: $5.9M
- Latest round: Series B (Jul 1, 2017)
- Investors on record: 1

## About

Established in 2010 and based in Tianjin, China, Minkang Biological Group operates as a diabetes monitoring service provider dedicated to providing blood glucose monitors and other products. It has subsidiaries in Suzhou and Anhui. The company acquired certifications such as ISO9001 and CE certificate. In 2016, SY series blood glucose meters are officially on sale. In January 2020, the company raised CNY 150 million in Pre-IPO led by new investor China Venture Capital.

The company mainly provides blood glucose monitor. It provides continuous glucose monitoring, blood sugar product series, blood lipid product series, blood ketone product series, uric acid product series, and myocardial infarction product series. The product covers multiple diabetes index tests such as blood sugar, glycosylated hemoglobin, uric acid, etc. Minkang Biological Group also provides insulin pen needles, medical surgical masks and other products.

The company generates revenue by providing blood glucose monitor such as blood sugar product series, blood lipid product series, blood ketone product series, uric acid product series, and myocardial infarction product series.

## Funding rounds

- Series B, Jul 1, 2017, $5.9M — Shanshan Venture Capital

## Investors

- Shanshan Venture Capital (https://capitalatlas.ai/funds/shanshan-venture-capital) — Series B